<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">279</journal-id><journal-id journal-id-type="pmc-domain">brjclinpharm</journal-id><journal-id journal-id-type="publisher-id">BCP</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4799932</article-id><article-id pub-id-type="pmcid-ver">PMC4799932.1</article-id><article-id pub-id-type="pmcaid">4799932</article-id><article-id pub-id-type="pmcaiid">4799932</article-id><article-id pub-id-type="pmid">26574160</article-id><article-id pub-id-type="doi">10.1111/bcp.12828</article-id><article-id pub-id-type="publisher-id">BCP12828</article-id><article-id pub-id-type="other">MP-00644-14.R2</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Pharmacokinetics</subject></subj-group><subj-group subj-group-type="heading"><subject>Pharmacokinetics</subject></subj-group></article-categories><title-group><article-title>A comparison of the intrasubject variation in drug exposure between generic and brand&#8208;name drugs: a retrospective analysis of replicate design trials</article-title><alt-title alt-title-type="right-running-head">Intrasubject variability in drug exposure upon drug switching</alt-title><alt-title alt-title-type="left-running-head">Y. Yu et al.</alt-title></title-group><contrib-group><contrib id="bcp12828-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Yu</surname><given-names initials="Y">Yang</given-names></name><xref ref-type="aff" rid="bcp12828-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bcp12828-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="bcp12828-cr-0002" contrib-type="author"><name name-style="western"><surname>Teerenstra</surname><given-names initials="S">Steven</given-names></name><xref ref-type="aff" rid="bcp12828-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="bcp12828-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="bcp12828-cr-0003" contrib-type="author"><name name-style="western"><surname>Neef</surname><given-names initials="C">Cees</given-names></name><xref ref-type="aff" rid="bcp12828-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="bcp12828-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="bcp12828-cr-0004" contrib-type="author"><name name-style="western"><surname>Burger</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="bcp12828-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="bcp12828-cr-0005" contrib-type="author"><name name-style="western"><surname>Maliepaard</surname><given-names initials="M">Marc</given-names></name><xref ref-type="aff" rid="bcp12828-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="bcp12828-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Pharmacology and Toxicology</named-content><institution>CARIM, Maastricht University Medical Centre</institution><named-content content-type="city">Maastricht</named-content><country country="NL">The Netherlands</country></aff><aff id="bcp12828-aff-0002" content-type="private-address"><label><sup>2</sup></label><institution>Medicines Evaluation Board</institution><named-content content-type="city">Utrecht</named-content><country country="NL">The Netherlands</country></aff><aff id="bcp12828-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Health Evidence, Biostatistics Section</named-content><institution>Radboud University Medical Centre</institution><named-content content-type="city">Nijmegen</named-content><country country="NL">The Netherlands</country></aff><aff id="bcp12828-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Pharmacology and Toxicology</named-content><institution>CAPHRI, Maastricht University Medical Centre</institution><named-content content-type="city">Maastricht</named-content><country country="NL">The Netherlands</country></aff><aff id="bcp12828-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Pharmacy</named-content><institution>Radboud University Nijmegen Medical Centre</institution><named-content content-type="city">Nijmegen</named-content><country country="NL">The Netherlands</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Correspondence<break/>
Ms Yang Yu, Medicines Evaluation Board, P.O. Box 8275, 3503 RG Utrecht, The Netherlands.<break/>
Tel.: +31 88 224 8381<break/>
Fax: +31 88 224 8001<break/>
E&#8208;mail: <email>a.yu@cbg-meb.nl</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2016</year></pub-date><volume>81</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">266936</issue-id><issue-id pub-id-type="doi">10.1111/bcp.v81.4</issue-id><fpage>667</fpage><lpage>678</lpage><history><date date-type="received"><day>10</day><month>12</month><year>2014</year></date><date date-type="rev-recd"><day>27</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>09</day><month>11</month><year>2015</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2017</year></date></event><event event-type="pmc-live"><date><day>01</day><month>04</month><year>2017</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2017-05-08 18:40:24.363"><day>08</day><month>05</month><year>2017</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2015 The British Pharmacological Society</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="BCP-81-667.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:BCP-81-667.pdf"/><abstract><sec id="bcp12828-sec-0001"><title>AIMS</title><p>The aim of the present study was to investigate whether differences in total and peak drug exposure upon generic substitution are due to differences between formulations or to intrasubject pharmacokinetic variability of the active substance.</p></sec><sec id="bcp12828-sec-0002"><title>Methods</title><p>The study was designed as a retrospective reanalysis of existing studies. Nine replicate design bioequivalence studies representing six drug classes &#8211; i.e. for alendronate, atorvastatin, cyclosporin, ebastine, exemestane, mycophenolate mofetil, and ropinirole &#8211; were retrieved from the Dutch Medicines Regulatory Authority.</p></sec><sec id="bcp12828-sec-0003"><title>Results</title><p>In most studies, the intrasubject variability in total and peak drug exposure was comparable for the brand&#8208;name [in the range 0.01&#8211;0.24 for area under the concentration&#8211;time curve (AUC<sub>t</sub>) and 0.02&#8211;0.29 for peak plasma concentration (C<sub>max</sub>) on a log scale] and generic (0.01&#8211;0.23 for AUC<sub>t</sub> and 0.08&#8211;0.33 for C<sub>max</sub>) drugs, and was comparable with the intrasubject variability upon switching between those drugs (0.01&#8211;0.23 for AUC<sub>t</sub> and 0.06&#8211;0.33 for C<sub>max</sub>). The variance related to subject&#8208;by&#8208;formulation interaction could be considered negligible (&#8211;0.069 to 0.047 for AUC<sub>t</sub> and &#8211;0.091 to 0.02 for C<sub>max</sub>).</p></sec><sec id="bcp12828-sec-0004"><title>Conclusion</title><p>In the investigated studies, the variation in total and peak exposure seen when a patient is switched from a brand&#8208;name to a generic drug is comparable with that seen following repeated administration of the brand&#8208;name drug in the patient. Only the intrasubject variability seems to play a crucial and decisive role in the variation in drug exposure seen; no additional formulation&#8208;dependent variation in exposure is observed upon switching. Thus, our data support that, for the medicines that were included in the present investigation, from a clinical pharmacological perspective, the benefit&#8211;risk balance of a generic drug is comparable with that of the brand&#8208;name drug.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="bcp12828-kwd-0003">bioequivalence study</kwd><kwd id="bcp12828-kwd-0007">generic drugs</kwd><kwd id="bcp12828-kwd-0008">intrasubject variability</kwd></kwd-group><counts><page-count count="12"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>bcp12828</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.8.5 mode:remove_FC converted:20.03.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="bcp12828-cit-0000"><string-name name-style="western"><surname>Yu</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Teerenstra</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Neef</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Burger</surname>, <given-names>D.</given-names></string-name>, and <string-name name-style="western"><surname>Maliepaard</surname>, <given-names>M.</given-names></string-name> (<year>2016</year>) <article-title>A comparison of the intrasubject variation in drug exposure between generic and brand&#8208;name drugs: a retrospective analysis of replicate design trials</article-title>. <source>Br J Clin Pharmacol</source>, <volume>81</volume>: <fpage>667</fpage>&#8211;<lpage>678</lpage>. doi: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1111/bcp.12828">10.1111/bcp.12828</ext-link>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.12828</pub-id><pub-id pub-id-type="pmcid">PMC4799932</pub-id><pub-id pub-id-type="pmid">26574160</pub-id></mixed-citation>
</p></notes></front></article></pmc-articleset>